Chronic Graft Versus Host Disease
Specialty Channel

Featured Article
________ yields tolerability for the prevention of acute graft-versus-host disease by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the…
True or False: Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
True or false: The efficacy of allo-HCT depends on the ability of donor T-cells to mediate a potent anti-tumor response in transplant recipients, known as the graft-versus-tumor effect.
True or False: This year, Ruxolitinib, a selective Janus kinase inhibitor, showed potential efficacy for glucocorticoid-refractory acute GVHD in a phase 2 trial.
True or False: Itpkb signaling is essential to drive acute GVHD pathogenesis and sustain active chronic GVHD.
In a phase 2 clinical trial, which prophylaxis regimens yielded the best GVHD-free relapse-free survival in adults who underwent reduced-intensity conditioning allogeneic hematopoietic cell…
True or False: Intact inositol-trisphosphate 3-kinase B signaling is essential to drive acute graft versus host disease pathogenesis and sustain active chronic GVHD.
True or False: Although DKK3 is a novel biomarker for chronic graft-versus-host disease, further studies are needed to determine the biological functions of DKK3 in the pathogenesis of cGVHD.

News

Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
Study findings suggest that an association exists between plasma DKK3 concentrations and nonrelapse mortality in patients with cGVHD.
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.
Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Interactive Features

________ yields tolerability for the prevention of acute graft-versus-host disease by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the…
True or False: Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria.
True or false: The efficacy of allo-HCT depends on the ability of donor T-cells to mediate a potent anti-tumor response in transplant recipients, known as the graft-versus-tumor effect.
True or False: This year, Ruxolitinib, a selective Janus kinase inhibitor, showed potential efficacy for glucocorticoid-refractory acute GVHD in a phase 2 trial.
Stay in the know.
OncNet Newsletter